Objective: Patients with breast and colorectal cancer can use oral and injectable chemotherapy treatments. The objective of this study is to assess the satisfaction in patients using capecitabine (oral chemotherapy) in comparison with their previous experiences with injectable chemotherapies. Also, we aimed to compare the preference of patients on this oral drug to the injectable chemotherapy treatments. Methods: Quantitative study performed with 150 oncology patients with breast and colorectal cancer (from all Brazilian regions) who use capecitabine as a treatment. A structured questionnaire with 10 answers assessing six attributes was used. Results: The average age of the patients is 61 years, with these patients presenting cancer for an average of 4 years. Eighty-nine percent of the patients use capecitabine as monotherapy, and the rest use it combined with injectable treatments. Comparing capecitabine with injectable regimens, 89% of the studied subjects prefer the oral treatment. Capecitabine is best evaluated than the injectable treatments in the attributes: practicability, freedom, quality of life, efficacy and side effects. Treatments were assessed in a similar way about the item cost. Approximately third quarters consider capecitabine as efficient; such rate is slightly higher than the observed for injectable chemotherapy: 75% vs. 58%. Conclusion: Capecitabine is largely approved by its users, with 89% of them preferring it in comparison with the injectable treatments. The oral chemotherapy has as positive differences, in the perception of its users, practicability and freedom.